ConductScience.org, home

Paper29972759

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Abou-Alfa GK and 21 others. N Engl J Med, 2018. Cited by 1,923 papers, by iCite.

Cite this record

ConductScience Library. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. Papers, record 29972759. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29972759

Download JSON
Disease
hepatocellular carcinoma478 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
PubMed
Journal
N Engl J Med
PubMed
Year
2018
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
1,923
iCite
Relative citation ratio, by iCite
72.2
iCite
Revised in PubMed
2024-10-03
PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Abou-Alfa GKGhassan K
2Meyer TTim
3Cheng ALAnn-Lii
4El-Khoueiry ABAnthony B
5Rimassa LLorenza
6Ryoo BYBaek-Yeol
7Cicin IIrfan
8Merle PPhilippe
9Chen YYenHsun
10Park JWJoong-Won
11Blanc JFJean-Frederic
12Bolondi LLuigi
13Klümpen HJHeinz-Josef
14Chan SLStephen L
15Zagonel VVittorina
16Pressiani TTiziana
17Ryu MHMin-Hee
18Venook APAlan P
19Hessel CColin
20Borgman-Hagey AEAnne E

Source PubMed

See all 22 authorsDownload CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AnilidesMajor topic
Antineoplastic AgentsMajor topic
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
PyridinesMajor topic
Receptor Protein-Tyrosine KinasesMajor topic
Adult
Aged
Aged, 80 and over
Disease-Free Survival
Double-Blind Method
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMedNIH RePORTER
P30 CA014089NCI NIH HHSUnited StatesP30CA014089PubMedNIH RePORTER

Download CSV of grants

Trials6

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01908426Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior SorafenibDerived from the trialYesClinicalTrials.gov
NCT05134532Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCCResultsClinicalTrials.gov
NCT05425004Cabozantinib for Patients With Recurrent or Progressive MeningiomaBackgroundClinicalTrials.gov
NCT05831969Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCCBackgroundClinicalTrials.gov
NCT06007846A Prospective Study of Memantine in Patients With Cirrhosis and Liver CancerBackgroundClinicalTrials.gov
NCT06535737A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and BevacizumabBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in30285325Cabozantinib in Hepatocellular Carcinoma.https://conductscience.org/library/papers/30285325PubMed
Comment in30881965Cabozantinib and the moving field of systemic treatments in advanced hepatocellular carcinoma.https://conductscience.org/library/papers/30881965PubMed
Comment in31098366Cabozantinib for advanced hepatocellular carcinoma.https://conductscience.org/library/papers/31098366PubMed

Download CSV of comments and corrections

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119095497Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009https://conductscience.org/library/papers/19095497PubMed
27973215Interim analysis: the alpha spending function approach.Stat Med1994https://conductscience.org/library/papers/7973215PubMed
326959385Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.Cancer2016https://conductscience.org/library/papers/26959385PubMed
427834845The Receptor Tyrosine Kinase AXL in Cancer Progression.Cancers (Basel)2016https://conductscience.org/library/papers/27834845PubMed
522270953Targeting MET in cancer: rationale and progress.Nat Rev Cancer2012https://conductscience.org/library/papers/22270953PubMed
621926191Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.Mol Cancer Ther2011https://conductscience.org/library/papers/21926191PubMed
725568918The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.Nat Rev Cancer2014https://conductscience.org/library/papers/25568918PubMed
822424438EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2012https://conductscience.org/library/papers/22424438PubMed
926364599Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.Oncogene2016https://conductscience.org/library/papers/26364599PubMed
1012726861Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.Cancer Cell2003https://conductscience.org/library/papers/12726861PubMed
1124700742Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.Clin Cancer Res2014https://conductscience.org/library/papers/24700742PubMed
1227279544Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.Lancet Oncol2016https://conductscience.org/library/papers/27279544PubMed
1319406039NCCN clinical practice guidelines in oncology: hepatobiliary cancers.J Natl Compr Canc Netw2009https://conductscience.org/library/papers/19406039PubMed
1428426123Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.Ann Oncol2017https://conductscience.org/library/papers/28426123PubMed
1529625879Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.Lancet Oncol2018https://conductscience.org/library/papers/29625879PubMed
1626790028Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.Cancer Sci2016https://conductscience.org/library/papers/26790028PubMed
1723980090Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.J Clin Oncol2013https://conductscience.org/library/papers/23980090PubMed
1818650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
1919097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
2026406150Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.N Engl J Med2015https://conductscience.org/library/papers/26406150PubMed

See all 29 referencesDownload CSV of references

Cited by1,398

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,923 citations.

PMIDTitleJournalYearIn PapersSource
42964795Same organ, divergent immunity: T-cell exhaustion versus stromal exclusion in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.Front Immunol2026https://conductscience.org/library/papers/42964795PubMed
4295339568Ga/177Lu-Labeled Seribantumab as the Theranostic Drugs in Treating HER3-Positive Hepatocellular Carcinoma.Drug Des Devel Ther2026https://conductscience.org/library/papers/42953395PubMed
42930143β-Catenin Signaling in Hepatocellular Carcinoma: Mechanisms of Therapeutic Resistance and Emerging Therapeutic Strategies.Curr Oncol2026https://conductscience.org/library/papers/42930143PubMed
42927511Regorafenib induces ferroptosis in hepatocellular carcinoma via the EGFR-TNF/NF-κB signaling axis.Apoptosis2026https://conductscience.org/library/papers/42927511PubMed
42907488Inhibition of ACSS2 enhances cabozantinib sensitivity by blocking TFEB-induced autophagic flux in hepatocellular carcinoma.Br J Cancer2026https://conductscience.org/library/papers/42907488PubMed
42882770Re-Evaluating Multi-Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Combined Therapy in Colorectal Cancer: A Preclinical Study.Cancers (Basel)2026https://conductscience.org/library/papers/42882770PubMed
42870868Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy.Front Oncol2026https://conductscience.org/library/papers/42870868PubMed
42836499Hepatocellular Carcinoma in the Eastern World: Screening, Diagnosis, Staging and Treatment.Curr Pharm Des2026https://conductscience.org/library/papers/42836499PubMed
42819747Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe.Lancet Reg Health Eur2026https://conductscience.org/library/papers/42819747PubMed
42799607Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma.Hepat Oncol2026https://conductscience.org/library/papers/42799607PubMed
42795014Systemic Therapy for Advanced Hepatocellular Carcinoma with Impaired Liver Function: Navigating the Evidence Gap.Cancers (Basel)2026https://conductscience.org/library/papers/42795014PubMed
42793258AI-Powered Marine Drug Discovery: A Putative Dual c-Met/VEGFR2 Lead Candidate for Hepatocellular Carcinoma via Deep Learning and Multiscale Simulation.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42793258PubMed
42769860From mechanisms to practice: risk management and multidisciplinary decision-making for systemic treatment-related liver injury in HBV-associated hepatocellular carcinoma.Front Pharmacol2026https://conductscience.org/library/papers/42769860PubMed
42707173The Evolving Landscape of Hepatocellular Carcinoma Therapy: From Conventional Modalities to TME-Responsive Prodrug Design Strategies.Drug Des Devel Ther2026https://conductscience.org/library/papers/42707173PubMed
42697413Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis.Cell Mol Gastroenterol Hepatol2026https://conductscience.org/library/papers/42697413PubMed
42678589Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.Target Oncol2026https://conductscience.org/library/papers/42678589PubMed
42676671Cabozantinib-associated therapy-refractory lower-leg ulcers in metastatic renal cell carcinoma.JAAD Case Rep2026https://conductscience.org/library/papers/42676671PubMed
42652118Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies.Biomedicines2026https://conductscience.org/library/papers/42652118PubMed
426451781D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL.Cells2026https://conductscience.org/library/papers/42645178PubMed
42645031Tumor Microenvironment-on-a-Chip: Construction and Application in Traditional Chinese Medicine Anti-Tumor Therapy.Biosensors (Basel)2026https://conductscience.org/library/papers/42645031PubMed

See all 1,398 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
REGORAFENIBCHEMBL1946170Results1https://conductscience.org/library/drugs/CHEMBL1946170ChEMBL
CABOZANTINIBCHEMBL2105717Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2105717ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29972759

GET https://conductscience.org/api/papers/v1/29972759/authors?page=2